

# A Deletion in Tropomyosin-Related Kinase B and the Development of Human Anxiety

Carl Ernst, Brigitte Wanner, Jelena Brezo, Frank Vitaro, Richard Tremblay, and Gustavo Turecki

**Background:** The tropomyosin-related kinase B (TrkB)/brain-derived neurotrophic factor system has been associated with psychiatric disorders, and animal models of defects in this system suggest that it might have a particular role in anxiety.

**Methods:** DNA sequencing and cloning were used to identify a mutation in *TrkB*, and four different cell lines were used to assess functionality. Clinical samples were from a 22-year longitudinal cohort representative of the Quebec general population ( $n = 640$  subjects), randomly selected when they were in kindergarten. Anxiety-related traits were measured with the Social Behaviour Questionnaire, the Diagnostic Assessment of Personality Pathology-Brief Questionnaire, and the Diagnostic Interview Schedule for DSM-III-R.

**Results:** An 11 base pair deletion in *TrkB* is significantly associated with increases in anxiety traits during childhood and the development of anxiety disorders in adulthood. We found that this deletion impaired transcription in some human cell lines.

**Conclusions:** The identification of this deletion provides additional support for the role of TrkB in modulating anxiety-related traits in human.

**Key Words:** Brain, generalized anxiety disorder, genetics, longitudinal study, panic disorder, TrkB

Tropomyosin-related kinase B (TrkB) (also known as NTRK2) is a neurotrophic factor receptor in the central nervous system that plays a critical role in synaptic modeling, neurodevelopment, and cell signaling (1,2). Tropomyosin-related kinase B is a transmembrane receptor that is bound with high affinity by brain-derived neurotrophic factor (BDNF), and this interaction leads to conformation changes and phosphorylation at intracellular domains of TrkB. These ligand-induced changes generate intracellular signal cascades leading to, among other effects, gene transcription. A number of the genes regulated by TrkB-induced signaling cascades are related to cell growth, cell survival, and cytoskeletal dynamics (3).

Functional studies of TrkB in mice suggest that the gene plays a key role in traits implicated in anxiety. In mouse transgenic studies, overexpression of TrkB reduces anxiety (4), whereas deletion of *TrkB* in forebrain induces impulsive reactions to novel stimuli and inappropriate coping responses when facing stressful paradigms (5). Furthermore, deletion of *TrkB* in adult progenitor cells in the hippocampus increases anxious behavior in mice (6). Studies investigating the effects of BDNF also suggest a role in anxiety—in particular, the finding that reduced neuronal release of BDNF leads to increased anxiety-like traits in mice (7,8). Conceptually, TrkB has been linked to psychiatric illness in humans through the neurotrophin hypothesis of stress-related mood disorders (9,10).

In the current study, we identified an 11 base pair (bp) deletion in a human *TrkB* promoter. We hypothesized that this deletion would be associated with reduced expression of TrkB and that

carriers of this deletion would have higher scores on surveys of anxiety-related traits compared with individuals carrying two wild-type TrkB alleles.

## Methods and Materials

Comprehensive descriptions of the community cohort used in this study have been previously described (11). Briefly, 640 (364 female participants, 57%) members of a cohort followed since 1986 were randomly selected from French-speaking public schools in Quebec, Canada when they were in kindergarten. Only subjects whose parents were born in Quebec and whose mother tongue was French were included in this study (12). Included in the present study were subjects that had complete childhood and adult data on behavioral traits through all assessment waves and complete adult psychiatric information and provided a DNA sample ( $n = 640$ ). Subjects were assessed on a series of behavioral and psychiatric questionnaires, a description of which can be found in the Methods and Materials in Supplement 1 along with all statistical analyses. All experiments and data collection were carried out in accordance with the institutional review boards of McGill University and the University of Montréal.

Full description of molecular experiments and cell transfection studies can be found in Methods and Materials in Supplement 1.

## Results


While screening *TrkB* in a separate study performed in the French-Canadian population (13), we found two subjects with an 11 bp deletion (Figures 1A and 1B). Although the *TrkB* structure is complex (14,15), this deletion is located in a region thought to be the promoter (14). The wildtype *TrkB* sequence contains a single AluI digestion site within the deleted sequence, allowing for identification of deletion carriers by means of a restriction enzyme assay (Figure 1C). Given the size of the deletion, we could detect deletion carriers by running out the polymerase chain reaction products of DNA amplified through primers flanking the deletion site in agarose gels; in individuals with the deletion, we observed two bands (Figure 1D). Finally, we sequenced both mutant and wildtype bands (Figure 1E) and cloned the deletion (Figure 1F).

We cloned a 1.61 kb fragment that included the deletion region as well as upstream sequences. Consistent with a previous report

From the McGill Group for Suicide Studies (CE, JB, GT), Department of Psychiatry (CE, GT), McGill University; Research Unit on Children's Psychosocial Maladjustment (BW, FV, RT), University of Montréal, Montreal, Canada; and the School of Public Health and Population Sciences (RT), University College Dublin, Dublin, Ireland.

Address correspondence to Gustavo Turecki, M.D., Ph.D., McGill University, McGill Group for Suicide Studies, Department of Psychiatry, Pavilion Frank B Common, 6875 LaSalle Blvd., Montreal, QC, Canada H4H 1R3; E-mail: [gustavo.turecki@mcgill.ca](mailto:gustavo.turecki@mcgill.ca).


Received Jun 22, 2010; revised Aug 23, 2010; accepted Oct 7, 2010.



**Figure 1.** Identification of a deletion in tropomyosin-related kinase B (*TrkB*). **(A)** General structure of *TrkB*, with truncated isoforms (T2 and T1) shown. **(B)** A promoter region of *TrkB*, including the deletion (underlined and emboldened, with AluI cut site, AGCT, emphasized). Numbers represent start and end of sequence region from hg19 genome build. **(C)** Restriction digestion (*AluI*) of the deleted fragment. Subjects with the deletion (MUT) are all heterozygous for the mutation, and therefore one-half of the DNA product is protected from *AluI* digestion. Note the presence of the full length band in MUT lanes, which are absent in all wildtype (WT) lanes. **(D)** Gel electrophoresis showing MUT and WT subjects. Note the presence of an extra band in MUT lanes. **(E)** Sequencing from MUT and WT bands shown in **D**. Deletion region is depicted with an arrow. **(F)** Sequencing of the cloned bands in MUT and WT subjects from **D**. **(G and H)** Results of luciferase transfection assays with negative control (Luc plasmid), construct with the deletion (TrkB del) and wildtype construct (TrkB WT).

(14), this region showed promoter activity both in COS7 cells and HEK293 cells (Figure 1G), where constructs with the deletion showed lower luciferase activity than wildtype constructs (COS7:  $t = 4.33, p < .05$ ; 1.41-fold decrease; HEK293:  $t = 4.1, p < .01$ ; 1.37-fold decrease). We also assessed human astrocytoma and neuroblastoma cell lines (Figure 1H). In astrocytes, we found a significant

difference between the wildtype and mutant constructs ( $t = 2.87; p < .05$ , 1.68-fold decrease). However, in the neuronal cell line, we observed no significant difference between mutant and wildtype constructs ( $t = .79, p > .05$ ; 1.23-fold decrease), although baseline luciferase activity was essentially undetectable with either wildtype or mutant construct in this cell line. We note that a positive control



**Figure 2.** Relationship between tropomyosin-related kinase B (*TrkB*) deletion and anxiety traits in childhood longitudinal trajectory profiles of parent ratings of anxiousness. Cohort members were children 6–12 years of age, as noted on the x axis. Black shading represents high anxiety trajectories, whereas gray shading represents low anxiety trajectories. The number of subjects and percentages of subjects with the deletion ( $N_{DEL}$ ) is noted. High and low anxiety subjects were determined mathematically with six items testing anxiety on the Social Behavior Questionnaire (SBQ).

(not shown) transfected simultaneously but independently demonstrated strong promoter activity in all cell lines.

We hypothesized that individuals carrying this *TrkB* deletion would be more likely to present increased measures of anxiety traits. To test this hypothesis, we investigated 640 participants from a 22-year longitudinal study with a representative sample of kindergarten children from the province of Quebec (16). In total, we found 20 subjects (3.1%) of 640 with the deletion, of which 8 were male.

With a clustering technique for longitudinal data (17), we identified five trajectories of anxiety with different longitudinal profiles based on annual parent ratings of anxiety traits from 6 to 12 years of age (Figure 2). Individuals following the high ( $n = 146$ ;  $N_{DEL} = 6$ ; 4.1%) and moderately high ( $n = 321$ ;  $N_{DEL} = 13$ ; 4.0%) anxiety trajectories were significantly more likely to carry a *TrkB* allele with a deletion (Fisher  $p = .01$ ) when compared with individuals following decreasing low ( $n = 26$ ;  $N_{DEL} = 0$ ), low ( $n = 118$ ;  $N_{DEL} = 1$ , .6%), or very low ( $n = 29$ ;  $N_{DEL} = 0$ ) trajectories. Similar results were observed for teacher-rated scores of anxiety from 6 to 12 years of age (not shown).

At 21–23 years of age, individuals were reassessed for anxiety traits with a personality trait questionnaire (18,19). Analyses showed that the deletion was associated with higher anxiousness scores on the Diagnostic Assessment of Personality Pathology-Brief Questionnaire [ $\beta = .09$ ,  $t(1) = 2.27$ ,  $p < .05$ ]. This association was robust when covariates were considered [ $\beta = .09$ ,  $t(1) = 2.21$ ,  $p < .05$ ]. All subjects were also assessed for the presence of psychiatric disorders at this age period with the Diagnostic Interview Schedule for DSM-III-R. Individuals carrying the *TrkB* allele with the deletion were significantly more likely to be diagnosed with generalized anxiety disorder (GAD) [ $\chi^2(1) = 4.58$ ,  $p < .05$ ] or panic disorder (PD) [ $\chi^2(1) = 5.33$ ,  $p < .05$ ], even after adjusting for significant covariates (gender and early family adversity). Having the deletion increased the odds of GAD by approximately three times (odds ratio: 2.86; 95% confidence interval: 1.1–7.5) and of PD by approximately 3.5 times (odds ratio: 3.69; 95% confidence interval: 1.2–11.2) and explained 3% of the variance in both PD and GAD. We tested a series of moderation effects, results of which can be found in Supplement 1.

## Discussion

This report identifies a novel deletion in a promoter region of *TrkB* that affects transcription and is associated with differences in anxiety

traits in childhood and greater risk for developing specific anxiety disorders in adulthood. We characterized the deletion by comparing transcriptional activity of the wildtype and mutant constructs. In non-CNS cell lines we could consistently establish an effect of the deletion on transcription. We were able to show decreased luciferase activity in mutant compared with wildtype promoter constructs in a human astrocyte line, although this was not observed in a neuronal cell line. Both neuroblastoma and astrocytoma cell lines used in this study, however, showed decreased transfection efficiency compared with HEK293 and COS7 cells, and the use of a promoter positive control in these cancer cell lines ruled out the possibility of technical error. This suggests that the cell lines themselves are capable of inducing promoter activity in a promoter with well-characterized transcription factor binding sites. The neuroblastoma cell line used in this study exhibits low or no expression of the *MDR1* gene (<http://www.ATCC.org>), and altered expression of this gene has been suggested to functionally affect cells—possibly in altering trans-acting factors binding to particular DNA sequences (20). Further testing of other neuronal cell lines for the function of this *TrkB* mutation will be important. We note that in silico examinations of transcription factor binding sites (TRANSFAC database) found no direct binding targets, although predicted binding sites for *Sry* and *Pbx* family members are immediately upstream. The deletion might alter binding of transcription factors by altering the surrounding genomic environment.

We found that a higher proportion of children with the deletion were described as anxious by both parent and teacher ratings (19 children rated high anxiety vs. 1 child rated low anxiety). The use of different respondents and reliable well-validated instruments with respect to childhood and adult measures as well as the developmental and longitudinal study design represent strengths of this study. However, the low prevalence of the *TrkB* deletion (only 20 subjects were found heterozygous for the deletion of 640 total subjects) likely reduced the power of the statistical tests. This might explain why we did not find evidence regarding the common diathesis hypothesis. A further limitation of this study is that most subjects with high anxiety ratings did not have a deletion in the *TrkB* gene, and one subject with the deletion was not anxious. This could suggest that this 11 bp deletion can contribute to anxiety only in combination with other genetic variation. Nevertheless, this study further supports the association of the *TrkB*/BDNF system with the development of anxiety traits in humans.

*This work was supported by the Canadian Institute of Health Research MOP 79253. The author GT is a Fonds de la recherche en santé du Québec research fellow. The author CE received a scholarship from the Natural Sciences and Engineering Research Council of Canada. We thank Veronique Lebel, Sonia Rehal, Xiaoming Deng, and Jennie Yang for excellent technical assistance.*

*The authors report no biomedical interests or potential conflicts of interest.*

*Supplementary material cited in this article is available online.*

1. Klein R, Smeyne RJ, Wurst W, Long LK, Auerbach BA, Joyner AL, et al. (1993): Targeted disruption of the *trkB* neurotrophin receptor gene results in nervous system lesions and neonatal death. *Cell* 75:113–122.
2. Waterhouse EG, Xu B (2009): New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. *Mol Cell Neurosci* 42:81–89.
3. Minichiello L (2009): *TrkB* signalling pathways in LTP and learning. *Nat Rev Neurosci* 10:850–860.
4. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, et al. (2003): Activation of the *TrkB* neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. *J Neurosci* 23:349–357.

5. Zorner B, Wolfer DP, Brandis D, Kretz O, Zacher C, Madani R, *et al.* (2003): Forebrain-specific trkB-receptor knockout mice: Behaviorally more hyperactive than “depressive”. *Biol Psychiatry* 54:972–982.
6. Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M (2008): Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. *Proc Natl Acad Sci U S A* 105:15570–15575.
7. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, *et al.* (2006): Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science* 311:864–868.
8. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, *et al.* (2006): Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. *Science* 314: 140–143.
9. Duman RS, Monteggia LM (2006): A neurotrophic model for stress-related mood disorders. *Biol Psychiatry* 59:1116–1127.
10. Duman RS, Heninger GR, Nestler EJ (1997): A molecular and cellular theory of depression. *Arch Gen Psychiatry* 54:597–606.
11. Tremblay RE, Pihl RO, Vitaro F, Dobkin PL (1994): Predicting early onset of male antisocial behavior from preschool behavior. *Arch Gen Psychiatry* 51:732–739.
12. Tremblay RE, Schaal B (1996): Physically aggressive boys from age 6 to 12 years. Their biopsychosocial status at puberty. *Ann N Y Acad Sci* 794:192–207.
13. Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T, *et al.* (2009): Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. *Arch Gen Psychiatry* 66:22–32.
14. Martens LK, Kirschner KM, Warnecke C, Scholz H (2007): Hypoxia inducible factor-1 (HIF-1) is a transcriptional activator of the TrkB neurotrophin receptor gene. *J Biol Chem* 282:14379–14388.
15. Stoilov P, Castren E, Stamm S (2002): Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. *Biochem Biophys Res Commun* 290: 1054–1065.
16. Zoccolillo M, Vitaro F, Tremblay RE (1999): Problem drug and alcohol use in a community sample of adolescents. *J Am Acad Child Adolesc Psychiatry* 38:900–907.
17. Nagin D (1999): Analyzing developmental trajectories: A semi-parametric, group-based approach. *Psychol Methods* 4:139–157.
18. Livesley WJ, Jang KL, Vernon PA (1998): Phenotypic and genetic structure of traits delineating personality disorder. *Arch Gen Psychiatry* 55: 941–948.
19. Livesley WJ, Jackson DN (1986): The internal consistency and factorial structure of behaviors judged to be associated with DSM-III personality disorders. *Am J Psychiatry* 143:1473–1474.
20. Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, *et al.* (2004): Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. *BMC Med* 2:37.